Temporal hospitalization trends for inflammatory bowel disease in Taiwan [0.03%]
台湾地区炎症性肠病住院趋势的时空变化规律探究
Hao-Yu Wu,Meng-Tzu Weng,Chien-Chih Tung et al.
Hao-Yu Wu et al.
Background/aims: Scant population-based data are available for inflammatory bowel disease (IBD)-related hospitalization rates in Asian countries. We investigated the epidemiological trends of hospitalization rate and leng...
Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study [0.03%]
日本多中心注册研究中的单基因炎症性肠病极早期发病患者的特征分析
Natsuki Ito,Takahiro Kudo,Keisuke Jimbo et al.
Natsuki Ito et al.
Background/aims: Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed before 6 years of age, is highly influenced by genetic factors. Monogenic IBD is a type of enterocolitis caused by a single ...
Colitis-associated colorectal neoplasia in ulcerative colitis with primary sclerosing cholangitis: a nationwide study [0.03%]
溃疡性结肠炎伴原发性硬化性胆管炎的结直肠癌前病变全国流行病学研究报告
Koichi Komatsu,Takahide Shinagawa,Motoi Uchino et al.
Koichi Komatsu et al.
Background/aims: Ulcerative colitis (UC)-associated colorectal neoplasia (UCAN) in patients with UC and primary sclerosing cholangitis (PSC) has not been studied well in Japan. This retrospective study examined the clinic...
Evaluation of the Mayo endoscopic score in ulcerative colitis using a multimodal large language model: a human-blinded accuracy study [0.03%]
利用多模态大型语言模型评估Mayo内镜评分在溃疡性结肠炎中的准确性：一项盲法人类研究
Antonietta Gerarda Gravina,Raffaele Pellegrino,Giuseppe Imperio et al.
Antonietta Gerarda Gravina et al.
Background/aims: To date, some large language models (LLMs), such as Chat Generative Pre-trained Transformer 4-omni (ChatGPT-4o), can process images through visual transformer patching. An LLM analysis was conducted to as...
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study [0.03%]
针对中度至重度活动性克罗恩病的东亚患者的皮下注射古塞库单抗疗效和安全性：III期GRAVITI研究的事后亚组分析
Wenjia Liu,Hong Guo,Tae Oh Kim et al.
Wenjia Liu et al.
Background/aims: The GRAVITI (NCT05197049) study demonstrated efficacy and safety of guselkumab, a dual-acting interleukin- 23p19 subunit inhibitor, as subcutaneous (SC) induction and maintenance therapy in participants w...
Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan [0.03%]
布地奈德 Rectal 泡沫剂治疗溃疡性结肠炎的上市后大规模多中心前瞻性观察研究：最终报告
Masayuki Saruta,Teppei Omori,Akira Nagaki et al.
Masayuki Saruta et al.
Background/aims: Budesonide rectal foam was approved in Japan in 2017 for mild to moderate active ulcerative colitis (UC). This is the final report of post-marketing surveillance to evaluate real-world safety and effectiv...
Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan [0.03%]
难治性溃疡性结肠炎患者中米奎利珠维持治疗的疗效和安全性：日本单中心回顾性研究
Ichiro Mizushima,Yusuke Yoshimatsu,Hiroki Kiyohara et al.
Ichiro Mizushima et al.
Background/aims: Randomized controlled trials have confirmed the efficacy and safety of mirikizumab, an anti-interleukin-23p19 monoclonal antibody, for moderate-to-severe active ulcerative colitis (UC). However, there are...
First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study [0.03%]
一线生物制剂治疗选择对溃疡性结肠炎的临床结局影响显著：来自APPETISER研究的结果
Diari M&#x;Baye,Marianne Hupé,Marie Dodel et al.
Diari M&#x;Baye et al.
Background/aims: We compared the effectiveness of 2 strategies based on the choice of the first biologic owing to either drug efficacy or better acceptability in patients with ulcerative colitis (UC). ...
Association between anti-tumor necrosis factor alpha exposure and new-onset autoimmune diseases in inflammatory bowel disease: a nationwide case-control study in Korea [0.03%]
韩国炎症性肠病患者中抗肿瘤坏死因子α与新发自身免疫性疾病关联的全国病例对照研究
Shin Ju Oh,Ji Eun Kim,Su Jin Jeong et al.
Shin Ju Oh et al.
Background/aims: Autoimmune-related events following anti-tumor necrosis factor alpha (anti-TNF-α) therapy are increasingly reported, but population-level data on new-onset autoimmune disease in inflammatory bowel diseas...
Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study [0.03%]
乌帕替尼治疗炎症性肠病的现实世界有效性和安全性：一项单中心回顾研究
Ji Eun Kim,Yeong Chan Lee,Minjee Kim et al.
Ji Eun Kim et al.
Background/aims: Upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in clinical trials for inflammatory bowel disease (IBD); however, real-world data from Asian populations remain limited. ...